Trial · NCT01945762
Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
NCT01945762, Completed, Genzyme, a Sanofi Company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer. Trials, record NCT01945762. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01945762
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
- NCT number
- NCT01945762
- Status
- Completed
- Enrollment
- 31 participants, actual
- Lead sponsor
- Genzyme, a Sanofi Company
- Conditions
- Symptomatic, Aggressive, Sporadic, Unresectable, Locally, Advanced/Metastatic Medullary Thyroid Cancer (MTC)
- Interventions
- Vandetanib 300 mg
- First posted
- 2013-09-19
- Last updated
- 2024-12-18
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessment of Objective Response Rate | From enrollment until study completion, assessed up to 38 months | Assessment of Objective Response Rate \[using Response Evaluation Criteria In Solid Tumours (RECIST) 1.1\] |
| Primary | Assessment of Disease control rate | From enrollment until study completion, assessed up to 38 months | Assessment of Disease control rate \[using Response Evaluation Criteria In Solid Tumours (RECIST) 1.1\] |
| Primary | Assessment of Duration of Response | From enrollment until study completion, assessed up to 38 months | Assessment of Duration of Response (using RECIST 1.1) |
| Primary | Assessment of Progression Free Survival | From enrollment until study completion, assessed up to 38 months | Assessment of Progression Free Survival (using RECIST 1.1) |
| Primary | Evaluation of Safety by assessment of QTc prolongations | From enrollment until study completion, assessed up to 38 months | Assessment of QTc prolongations |
| Primary | Evaluation of Safety by assessment of Adverse Events | From enrollment until study completion, assessed up to 38 months | Assessment of Adverse Events |
| Primary | Evaluation of Safety by assessment of vital signs | From enrollment until study completion, assessed up to 38 months | Assessment of Vital signs |
| Primary | Evaluation of Safety by assessment of laboratory data | From enrollment until study completion, assessed up to 38 months | Assessment of Laboratory data |
| Secondary | Patient Characteristics | From enrollment until study completion, assessed up to 38 months | Patient demographics and medical history / Disease characteristics / Death / Treatment information |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01945762
GET https://conductscience.org/api/trials/v1/NCT01945762/registered